# **Supplementary Table 3.** Heterogeneity (I2) for relative pain with and without outliers, and relative function with and without outliers [25, 32, 40]

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Variable | No treatment, I2 (%) | Placebo with outliers, I2 (%) | Placebo without outliers, I2 (%) | All with outliers, I2 (%) | All without outliers, I2 (%) |
| Relative pain | | | | | |
| 1 month | 75 | 93 | 56 | 93 | 60 |
| 3 months | 21 | 95 | 0 | 95 | 0 |
| 6 months | 0 | 91 | 67 | 89 | 58 |
| 12 months | 0 | 99 | 62 | 99 | 47 |
| Relative function | | | | | |
| 1 month | 31 | 0 | 0 | 0 | 0 |
| 3 months | 76 | 93 | 22 | 91 | 44 |
| 6 months | 27 | 81 | 60 | 77 | 52 |
| 12 months | 0 | 99 | 31 | 97 | 74 |

“No treatment” trials did not include any outliers; I2 values of 30% to 60% may represent moderate heterogeneity; I2 > 75% represents considerable heterogeneity.